Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.
Bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs) have already demonstrated benefits for the treatment of cancer in several clinical studies, showing improved drug selectivity and efficacy. In particular, simultaneous targeting of prominent cancer antigens, such as EGF receptor (EGFR) and c-MET, by bsAbs has raised increasing interest for potentially circumventing receptor cross-talk and c-MET-mediated acquired resistance during anti-EGFR monotherapy. In this study, we combined the selectivity of EGFR × c-MET bsAbs with the potency of cytotoxic agents via bispecific antibody-toxin conjugation. Affinity-attenuated bispecific EGFR × c-MET antibody-drug conjugates demonstrated high in vitro selectivity toward tumor cells overexpressing both antigens and potent anti-tumor efficacy. Due to basal EGFR expression in the skin, ADCs targeting EGFR in general warrant early safety assessments. Reduction in EGFR affinity led to decreased toxicity in keratinocytes. Thus, the combination of bsAb affinity engineering with the concept of toxin conjugation may be a viable route to improve the safety profile of ADCs targeting ubiquitously expressed antigens.
From the Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, D-64287 Darmstadt, Germany.|Protein Engineering and Antibody Technologies and.
Carolin
C
Sellmann
Protein Engineering and Antibody Technologies and.
Achim
A
Doerner
Merck Research and Development, Merck KGaA, Frankfurter Strasse 250, D-64293 Darmstadt, Germany, and.
Christine
C
Knuehl
Protein Engineering and Antibody Technologies and.
Nicolas
N
Rasche
the EMD Serono Research and Development Institute, Billerica, Massachusetts 01821.
Vanita
V
Sood
From the Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, D-64287 Darmstadt, Germany.|Protein Engineering and Antibody Technologies and.
Simon
S
Krah
Protein Engineering and Antibody Technologies and.
Laura
L
Rhiel
From the Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, D-64287 Darmstadt, Germany.
Annika
A
Messemer
the EMD Serono Research and Development Institute, Billerica, Massachusetts 01821.
John
J
Wesolowski
Protein Engineering and Antibody Technologies and.
Mark
M
Schuette
Protein Engineering and Antibody Technologies and.
Stefan
S
Becker
Protein Engineering and Antibody Technologies and.
Lars
L
Toleikis
From the Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, D-64287 Darmstadt, Germany, Kolmar@Biochemie-TUD.de.
Harald
H
Kolmar
Protein Engineering and Antibody Technologies and Bjoern.Hock@merckgroup.com.
Bjoern
B
Hock
D000072283:A549 Cells; D018033:Antibodies, Bispecific / Q000276:immunology* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000276:immunology*; D056945:Hep G2 Cells; D006801:Humans; D000922:Immunotoxins / Q000276:immunology* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D019859:Proto-Oncogene Proteins c-met / Q000276:immunology*
D018033:Antibodies, Bispecific; D000922:Immunotoxins; C512478:EGFR protein, human; D066246:ErbB Receptors; D019859:Proto-Oncogene Proteins c-met
antibody engineering; anticancer drug; epidermal growth factor receptor (EGFR); sortase A; toxicity
Proteins. 1999 May 1;35(2):133-52
10223287
J Biol Chem. 2000 Mar 24;275(12):8806-11
10722725
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
11597399
J Mol Biol. 2003 Feb 28;326(4):1239-59
12589766
J Clin Oncol. 2003 Jul 15;21(14):2787-99
12860957
Trends Biotechnol. 1991 Apr;9(4):132-7
1367550
Science. 2003 Nov 21;302(5649):1364-8
14631033
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
PLoS Med. 2005 Mar;2(3):e73
15737014
Cancer Cell. 2005 Apr;7(4):301-11
15837620
Drug Discov Today. 2005 Sep 15;10(18):1237-44
16213416
Nat Rev Cancer. 2006 Oct;6(10):803-12
16990857
J Mol Biol. 2007 Mar 2;366(4):1209-21
17196978
Science. 2007 May 18;316(5827):1039-43
17463250
Cancer Sci. 2007 Aug;98(8):1275-80
17498200
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
18093943
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7
18180459
Methods Mol Biol. 2007;408:243-55
18314587
Cancer Cell. 2008 Apr;13(4):365-73
18394559
Exp Cell Res. 2008 Nov 1;314(18):3415-25
18817771
Br J Cancer. 2008 Nov 4;99(9):1415-25
18841159
Curr Oncol. 2009 Jan;16(1):16-26
19229368
Br J Cancer. 2008 Sep 16;99(6):911-22
19238632
Biotechnol Bioeng. 2009 Aug 15;103(6):1192-201
19459139
Protein Eng Des Sel. 2010 Apr;23(4):155-9
20130105
Protein Eng Des Sel. 2010 Apr;23(4):195-202
20299542
J Biotechnol. 2011 Apr 10;152(4):159-70
20883731
Clin Cancer Res. 2011 Feb 1;17(3):472-82
21098338
Protein Eng Des Sel. 2011 May;24(5):447-54
21498564
Nat Rev Drug Discov. 2011 Oct 31;10(11):798-800
22037028
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35
22128285
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S37-50
22128287
Nature. 2012 Jul 26;487(7408):500-4
22763439
Nature. 2012 Jul 26;487(7408):505-9
22763448
Nat Rev Drug Discov. 2012 Oct;11(10):751-61
22935759
Protein Eng Des Sel. 2012 Oct;25(10):551-9
22936109
Mol Cells. 2012 Dec;34(6):523-9
23180291
MAbs. 2013 Jan-Feb;5(1):13-21
23221464
Nat Rev Drug Discov. 2013 May;12(5):329-32
23629491
Cancer Discov. 2013 Jun;3(6):658-73
23729478
Oncogene. 2013 Dec 12;32(50):5593-601
23812422
Nat Biotechnol. 2013 Aug;31(8):753-8
23831709
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96
23882082
Biomaterials. 2013 Nov;34(34):8690-707
23953842
Clin Cancer Res. 2013 Dec 15;19(24):6751-65
24122793
Drug Discov Today. 2014 Jul;19(7):869-81
24239727
PLoS One. 2014 Jan 08;9(1):e84502
24416238
Nat Biotechnol. 2014 Feb;32(2):191-8
24463572
Int J Cancer. 2014 May 15;134(10):2424-36
24615768
J Clin Invest. 2014 Jul;124(7):3172-86
24865428
Ann N Y Acad Sci. 2014 Aug;1321:41-54
25123209
Clin Cancer Res. 2014 Dec 1;20(23):6059-70
25231402
Nat Rev Drug Discov. 2014 Nov;13(11):799-801
25359367
MAbs. 2015;7(2):377-89
25621507
Drug Discov Today. 2015 Jul;20(7):838-47
25728220
MAbs. 2015;7(3):461-9
25730144
Mol Cancer Ther. 2015 May;14(5):1141-51
25731184
ACS Chem Biol. 2015 Sep 18;10(9):2158-65
26131766
J Biol Chem. 2015 Oct 9;290(41):24689-704
26260789
Br J Cancer. 2016 Feb 16;114(4):362-7
26742008
MAbs. 2016;8(3):551-61
26761634
Ann Surg Oncol. 2016 Jun;23(6):2046-53
26812910
Mol Cancer Ther. 2016 Apr;15(4):661-9
26846818
Oncogene. 2016 Aug 25;35(34):4437-46
26853467
BMC Cancer. 2016 Feb 16;16:105
26879245
Clin Lung Cancer. 2016 Sep;17(5):375-383.e2
26926157
J Biol Chem. 2016 May 20;291(21):11337-47
27022022
MAbs. 2016 Jul;8(5):905-15
27097222
Biomedicines. 2014 Dec 03;2(4):359-383
28548076
Gene. 1993 Dec 27;137(1):109-18
7506686
Protein Eng. 1996 Jul;9(7):617-21
8844834